Ranbaxy Laboratories on Tuesday said it has received approval from the US health regulator to sell generic Alzheimer's disease drug, donepezil hydrochloride, in the American market with 180 days of exclusive marketing rights.
The company will be eligible to enter the US market with its generic version of Eisai Co's Aricept, the patent for which will expire in November this year.
"We are pleased with (US) Food and Drug Administration's decision of upholding Ranbaxy's sole eligibility to 180 days of marketing exclusivity for its generic version of Donepezil," a company spokesman said.
Buoyed by the approval, the shares of Ranbaxy soared 6.35 per cent, to hit a year-high of Rs 566. The scrip later ended at Rs 561.95, up 5.59 per cent.
Broader market was also firm and the Bombay Stock Exchange benchmark ended at 20,001.55, up 95.45 points.
Published on: Sep 21, 2010 5:18 AM IST